Cargando…

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease

BACKGROUND: Low anti-tumor necrosis factor α (TNFα) serum concentrations may result in lack of treatment response in patients with inflammatory bowel disease. We determined the anti-TNFα drug concentrations in patients with inflammatory bowel disease and investigated whether or not subtherapeutic dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlsen, Arne, Omdal, Roald, Leitao, Kristian Øgreid, Isaksen, Kjetil, Hetta, Anne Kristine, Karlsen, Lars Normann, Aabakken, Lars, Bolstad, Nils, Warren, David, Lundin, Knut E.A., Grimstad, Tore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881967/ https://www.ncbi.nlm.nih.gov/pubmed/29623105 http://dx.doi.org/10.1177/1756284818759930

Ejemplares similares

Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
por: Carlsen, Arne, et al.
Publicado: (2019)

Heat-shock protein 90α in plasma reflects severity of fatigue in patients with Crohn’s disease
por: Grimstad, Tore, et al.
Publicado: (2019)

Polyethylene glycol vs sodium picosulfate/magnesium citrate for colonoscopy preparation
por: Leitao, Kristian, et al.
Publicado: (2014)

Fatigue: a frequent and biologically based phenomenon in newly diagnosed celiac disease
por: Skjellerudsveen, Berit Mære, et al.
Publicado: (2022)

Less, but not gone—gluten-free diet effects on fatigue in celiac disease: a prospective controlled study
por: Skjellerudsveen, Berit Mære, et al.
Publicado: (2023)

Histologic healing and factors associated with complete remission following conventional treatment in ulcerative colitis
por: Steinsbø, Øyvind, et al.
Publicado: (2022)

Fatigue in celiac disease: A review of the literature
por: Skjellerudsveen, Berit M, et al.
Publicado: (2019)

High mobility group box 1 and a network of other biomolecules influence fatigue in patients with Crohn’s disease
por: Kvivik, Ingeborg, et al.
Publicado: (2023)

A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab
por: Carlsen, Arne, et al.
Publicado: (2019)

Fatigue is common and severe in patients with mastocytosis
por: Omdal, Roald, et al.
Publicado: (2018)

Anti-HMGB1 auto-Abs influence fatigue in patients with Crohn’s disease
por: Kvivik, Ingeborg, et al.
Publicado: (2021)

The Effect of Biological Treatment on Fatigue in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
por: Skjellerudsveen, Berit Mære, et al.
Publicado: (2023)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Adalimumab/infliximab: Lower serologic response: 6 case reports
Publicado: (2022)

Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis
por: Mase, Oliver, et al.
Publicado: (2023)

Acute Cardioembolic Stroke in the Setting of Subtherapeutic Anticoagulation
por: Ambatipudi, Ankit, et al.
Publicado: (2023)

Corrigendum to: Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
Publicado: (2021)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Alternative approaches to therapeutics and subtherapeutics for sustainable poultry production
por: Tabashsum, Zajeba, et al.
Publicado: (2023)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019)

A salmon peptide diet alleviates experimental colitis as compared with fish oil
por: Grimstad, Tore, et al.
Publicado: (2013)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
por: Orts, Beatriz, et al.
Publicado: (2022)

Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
por: Yang, Hua-Hua, et al.
Publicado: (2022)

Delayed cutaneous hypersensitivity reactions following the use of infliximab or adalimumab in patients with coronavirus disease 2019
por: Wang, Jing, et al.
Publicado: (2023)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Differential Impact of Subtherapeutic Antibiotics and Ionophores on Intestinal Microbiota of Broilers
por: Robinson, Kelsy, et al.
Publicado: (2019)

888. A Predictive Model for Subtherapeutic Vancomycin Troughs in Adults
por: Crisp, Sarah, et al.
Publicado: (2022)

Adalimumab and Infliximab in Crohn’s disease - real life data from a national retrospective cohort study
por: PREDA, C., et al.
Publicado: (2016)

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
por: Gu, Bonita, et al.
Publicado: (2022)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oq633cna55ik0pgcer5etgtkn7